Resistance to adefovir dipivoxil in patients with chronic hepatitis B
This article has no abstract so we have provided the first paragraph of the full text.
Although lamivudine is an effective treatment for chronic hepatitis B (CHB), HBV can develop lamivudine resistance. In these circumstances, adefovir dipivoxil is often used as an alternative therapy, but HBV sometimes develops resistance to this agent as well. In their retrospective study, Yeon and colleagues investigated the development of adefovir dipivoxil resistance in patients infected with lamivudine-resistant HBV.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cannabinoids hurt, heal in cirrhosisNature Medicine News and Views (01 Jun 2006)
Relapses in malariaNature News and Views (31 Mar 1977)
